{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:08Z","timestamp":1793761028868,"version":"4.6.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China","award":["No. 82172962"],"award-info":[{"award-number":["No. 82172962"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Luzhou Science and Technology Plan Project","award":["2023SYF107"],"award-info":[{"award-number":["2023SYF107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10787-026-02397-x","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:48:17Z","timestamp":1789624097000},"page":"6413-6430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations"],"prefix":"10.1007","volume":"34","author":[{"given":"Weihong","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueshui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Hin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-5833","authenticated-orcid":false,"given":"Zhangang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2397_CR1","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3389\/fimmu.2019.02688","volume":"10","author":"AK Ali","year":"2019","unstructured":"Ali AK, Komal AK, Almutairi SM et al (2019) Natural killer cell-derived IL-10 prevents liver damage during sustained murine cytomegalovirus infection. Front Immunol 10:2688. https:\/\/doi.org\/10.3389\/fimmu.2019.02688","journal-title":"Front Immunol"},{"issue":"4","key":"2397_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.placenta.2014.02.004","volume":"35","author":"J Alijotas-Reig","year":"2014","unstructured":"Alijotas-Reig J, Llurba E, Gris JM (2014) Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta 35(4):241\u2013248. https:\/\/doi.org\/10.1016\/j.placenta.2014.02.004","journal-title":"Placenta"},{"issue":"10","key":"2397_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L et al (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17(10):611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"2397_CR4","doi-asserted-by":"publisher","unstructured":"Almeida-Nunes DL, Mendes-Frias A, Silvestre R et al (2022) Immune Tumor microenvironment in ovarian cancer ascites. Int J Mol Sci 23(18). https:\/\/doi.org\/10.3390\/ijms231810692","DOI":"10.3390\/ijms231810692"},{"key":"2397_CR5","doi-asserted-by":"publisher","unstructured":"Alvarez M, Dunai C, Khuat LT et al (2020) IL-2 and anti-TGF-\u03b2 promote NK cell reconstitution and anti-tumor effects after syngeneic hematopoietic stem cell transplantation. Cancers (Basel) 12(11). https:\/\/doi.org\/10.3390\/cancers12113189","DOI":"10.3390\/cancers12113189"},{"issue":"10","key":"2397_CR6","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1084\/jem.20071143","volume":"204","author":"MM Andzelm","year":"2007","unstructured":"Andzelm MM, Chen X, Krzewski K et al (2007) Myosin IIA is required for cytolytic granule exocytosis in human NK cells. J Exp Med 204(10):2285\u20132291. https:\/\/doi.org\/10.1084\/jem.20071143","journal-title":"J Exp Med"},{"issue":"8","key":"2397_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/cji.0000000000000286","volume":"42","author":"X Ao","year":"2019","unstructured":"Ao X, Yang Y, Li W et al (2019) Anti-\u03b1FR CAR-engineered NK-92 cells display potent cytotoxicity against \u03b1fr-positive ovarian cancer. J Immunother 42(8):284\u2013296. https:\/\/doi.org\/10.1097\/cji.0000000000000286","journal-title":"J Immunother"},{"issue":"2","key":"2397_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","volume":"19","author":"DK Armstrong","year":"2021","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN et al (2021) Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(2):191\u2013226. https:\/\/doi.org\/10.6004\/jnccn.2021.0007","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2397_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/cmi.2014.40","volume":"12","author":"S Baek","year":"2015","unstructured":"Baek S, Kim YM, Kim SB et al (2015) Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I\/II trial. Cell Mol Immunol 12(1):87\u201395. https:\/\/doi.org\/10.1038\/cmi.2014.40","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"2397_CR10","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.7150\/ijbs.100355","volume":"20","author":"GL Beretta","year":"2024","unstructured":"Beretta GL, Costantino M, Mirra L et al (2024) Deubiquitinases in ovarian cancer: role in drug resistance and tumor aggressiveness. Int J Biol Sci 20(13):5208\u20135222. https:\/\/doi.org\/10.7150\/ijbs.100355","journal-title":"Int J Biol Sci"},{"key":"2397_CR11","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3389\/fimmu.2020.01090","volume":"11","author":"C Binder","year":"2020","unstructured":"Binder C, Cvetkovski F, Sellberg F et al (2020) CD2 immunobiology. Front Immunol 11:1090. https:\/\/doi.org\/10.3389\/fimmu.2020.01090","journal-title":"Front Immunol"},{"issue":"11","key":"2397_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.2009.91","volume":"89","author":"WA Boivin","year":"2009","unstructured":"Boivin WA, Cooper DM, Hiebert PR et al (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 89(11):1195\u20131220. https:\/\/doi.org\/10.1038\/labinvest.2009.91","journal-title":"Lab Invest"},{"issue":"3","key":"2397_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"2397_CR14","doi-asserted-by":"publisher","first-page":"dju200","DOI":"10.1093\/jnci\/dju200","volume":"106","author":"A Bruno","year":"2014","unstructured":"Bruno A, Ferlazzo G, Albini A et al (2014) A think tank of TINK\/TANKs: tumor-infiltrating\/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst 106(8):dju200. https:\/\/doi.org\/10.1093\/jnci\/dju200","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"2397_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473\u20132483. https:\/\/doi.org\/10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"issue":"7","key":"2397_CR16","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.3390\/curroncol29070365","volume":"29","author":"E Cameron","year":"2022","unstructured":"Cameron E, Lee V, Rana S et al (2022) Evolution of a systematic approach to smoking cessation in ontario\u2019s regional cancer centres. Curr Oncol 29(7):4604\u20134611. https:\/\/doi.org\/10.3390\/curroncol29070365","journal-title":"Curr Oncol"},{"issue":"4","key":"2397_CR17","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao X, Cai SF, Fehniger TA et al (2007) Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27(4):635\u2013646. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.014","journal-title":"Immunity"},{"issue":"3","key":"2397_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/0008-5472.Can-06-2264","volume":"67","author":"M Carlsten","year":"2007","unstructured":"Carlsten M, Bj\u00f6rkstr\u00f6m NK, Norell H et al (2007) DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 67(3):1317\u20131325. https:\/\/doi.org\/10.1158\/0008-5472.Can-06-2264","journal-title":"Cancer Res"},{"issue":"10","key":"2397_CR19","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/jci39065","volume":"119","author":"KA Charles","year":"2009","unstructured":"Charles KA, Kulbe H, Soper R et al (2009) The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 119(10):3011\u20133023. https:\/\/doi.org\/10.1172\/jci39065","journal-title":"J Clin Invest"},{"key":"2397_CR20","doi-asserted-by":"publisher","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8(2). https:\/\/doi.org\/10.1136\/jitc-2020-000957","DOI":"10.1136\/jitc-2020-000957"},{"issue":"10","key":"2397_CR21","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1007\/s00262-023-03510-7","volume":"72","author":"J Chen","year":"2023","unstructured":"Chen J, Hu J, Gu L et al (2023) Correction to: anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother 72(10):3401\u20133403. https:\/\/doi.org\/10.1007\/s00262-023-03510-7","journal-title":"Cancer Immunol Immunother"},{"key":"2397_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbrc.2021.05.066","volume":"563","author":"SH Choi","year":"2021","unstructured":"Choi SH, Jung D, Kim KY et al (2021) Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer. Biochem Biophys Res Commun 563:40\u201346. https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.066","journal-title":"Biochem Biophys Res Commun"},{"key":"2397_CR23","doi-asserted-by":"publisher","unstructured":"Chung YM, Khan PP, Wang H et al (2021) Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8\u2009+\u2009T cells via pharmacological activation of FOXO3. J Immunother Cancer 9(12). https:\/\/doi.org\/10.1136\/jitc-2021-002772","DOI":"10.1136\/jitc-2021-002772"},{"issue":"11","key":"2397_CR24","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/s1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633\u2013640. https:\/\/doi.org\/10.1016\/s1471-4906(01)02060-9","journal-title":"Trends Immunol"},{"issue":"12","key":"2397_CR25","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr. (2023) Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol 24(12):1994\u20132007. https:\/\/doi.org\/10.1038\/s41590-023-01659-y","journal-title":"Nat Immunol"},{"issue":"1","key":"2397_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai E, Zhu Z, Wahed S et al (2021) Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer 20(1):171. https:\/\/doi.org\/10.1186\/s12943-021-01464-x","journal-title":"Mol Cancer"},{"key":"2397_CR27","doi-asserted-by":"publisher","unstructured":"D\u0119bska-Zielkowska J, Moszkowska G, Zieli\u0144ski M et al (2021) KIR receptors as key regulators of NK cells activity in health and disease. Cells 10(7). https:\/\/doi.org\/10.3390\/cells10071777","DOI":"10.3390\/cells10071777"},{"issue":"27","key":"2397_CR28","doi-asserted-by":"publisher","first-page":"11413","DOI":"10.1074\/jbc.M117.786483","volume":"292","author":"FA Deuss","year":"2017","unstructured":"Deuss FA, Gully BS, Rossjohn J et al (2017) Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT). J Biol Chem 292(27):11413\u201311422. https:\/\/doi.org\/10.1074\/jbc.M117.786483","journal-title":"J Biol Chem"},{"key":"2397_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ceb.2021.02.008","volume":"71","author":"T Douanne","year":"2021","unstructured":"Douanne T, Griffiths GM (2021) Cytoskeletal control of the secretory immune synapse. Curr Opin Cell Biol 71:87\u201394. https:\/\/doi.org\/10.1016\/j.ceb.2021.02.008","journal-title":"Curr Opin Cell Biol"},{"issue":"suppl8","key":"2397_CR30","doi-asserted-by":"publisher","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA (2017) Real-world evidence in the treatment of ovarian cancer. Ann Oncol 28(suppl8):viii61\u2013viii65. https:\/\/doi.org\/10.1093\/annonc\/mdx443","journal-title":"Ann Oncol"},{"key":"2397_CR31","doi-asserted-by":"publisher","unstructured":"Eitler J, Rackwitz W, Wotschel N et al (2024) CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. J Immunother Cancer 12(2). https:\/\/doi.org\/10.1136\/jitc-2023-008155","DOI":"10.1136\/jitc-2023-008155"},{"issue":"9","key":"2397_CR32","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.4049\/jimmunol.178.9.5606","volume":"178","author":"J Endt","year":"2007","unstructured":"Endt J, McCann FE, Almeida CR et al (2007) Inhibitory receptor signals suppress ligation-induced recruitment of NKG2D to GM1-rich membrane domains at the human NK cell immune synapse. J Immunol 178(9):5606\u20135611. https:\/\/doi.org\/10.4049\/jimmunol.178.9.5606","journal-title":"J Immunol"},{"issue":"6383","key":"2397_CR33","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","volume":"359","author":"L Ferrari de Andrade","year":"2018","unstructured":"Ferrari de Andrade L, Tay RE, Pan D et al (2018) Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 359(6383):1537\u20131542. https:\/\/doi.org\/10.1126\/science.aao0505","journal-title":"Science"},{"issue":"5","key":"2397_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","volume":"47","author":"AG Freud","year":"2017","unstructured":"Freud AG, Mundy-Bosse BL, Yu J et al (2017) The broad spectrum of human natural killer cell diversity. Immunity 47(5):820\u2013833. https:\/\/doi.org\/10.1016\/j.immuni.2017.10.008","journal-title":"Immunity"},{"issue":"Pt 3","key":"2397_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","volume":"86","author":"S Gaikwad","year":"2022","unstructured":"Gaikwad S, Agrawal MY, Kaushik I et al (2022) Immune checkpoint proteins: signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol 86(Pt 3):137\u2013150. https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.014","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2397_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bbcan.2017.04.002","volume":"1868","author":"S Ganapathy-Kanniappan","year":"2017","unstructured":"Ganapathy-Kanniappan S (2017) Linking tumor glycolysis and immune evasion in cancer: emerging concepts and therapeutic opportunities. Biochim Biophys Acta Rev Cancer 1868(1):212\u2013220. https:\/\/doi.org\/10.1016\/j.bbcan.2017.04.002","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6670","key":"2397_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.add8831","volume":"382","author":"EP Gregoire","year":"2023","unstructured":"Gregoire EP, De Cian MC, Migale R et al (2023) The -KTS splice variant of WT1 is essential for ovarian determination in mice. Science 382(6670):600\u2013606. https:\/\/doi.org\/10.1126\/science.add8831","journal-title":"Science"},{"key":"2397_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1476-4598-9-11","volume":"9","author":"JA Gubbels","year":"2010","unstructured":"Gubbels JA, Felder M, Horibata S et al (2010) MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer 9:11. https:\/\/doi.org\/10.1186\/1476-4598-9-11","journal-title":"Mol Cancer"},{"key":"2397_CR39","doi-asserted-by":"publisher","first-page":"871106","DOI":"10.3389\/fimmu.2022.871106","volume":"13","author":"H Ham","year":"2022","unstructured":"Ham H, Medlyn M, Billadeau DD (2022) Locked and Loaded: mechanisms Regulating Natural Killer Cell Lytic Granule Biogenesis and Release. Front Immunol 13:871106. https:\/\/doi.org\/10.3389\/fimmu.2022.871106","journal-title":"Front Immunol"},{"issue":"1","key":"2397_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","volume":"11","author":"Y Han","year":"2018","unstructured":"Han Y, Xie W, Song DG et al (2018) Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol 11(1):92. https:\/\/doi.org\/10.1186\/s13045-018-0635-z","journal-title":"J Hematol Oncol"},{"issue":"15","key":"2397_CR41","doi-asserted-by":"publisher","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","volume":"8","author":"MS Hasim","year":"2022","unstructured":"Hasim MS, Marotel M, Hodgins JJ et al (2022) When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv 8(15):eabj3286. https:\/\/doi.org\/10.1126\/sciadv.abj3286","journal-title":"Sci Adv"},{"key":"2397_CR42","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.neo.2024.101065","volume":"58","author":"M He","year":"2024","unstructured":"He M, Ao X, Yang Y et al (2024) Construction of self-driving anti-\u03b1FR CAR-engineered NK cells based on IFN-\u03b3 and TNF-\u03b1 synergistically induced high expression of CXCL10. Neoplasia 58:101065. https:\/\/doi.org\/10.1016\/j.neo.2024.101065","journal-title":"Neoplasia"},{"key":"2397_CR43","doi-asserted-by":"publisher","first-page":"1360615","DOI":"10.3389\/fimmu.2024.1360615","volume":"15","author":"A Hrvat","year":"2024","unstructured":"Hrvat A, Benders S, Kimmig R et al (2024) Immunoglobulins and serum proteins impair anti-tumor NK cell effector functions in malignant ascites. Front Immunol 15:1360615. https:\/\/doi.org\/10.3389\/fimmu.2024.1360615","journal-title":"Front Immunol"},{"issue":"5","key":"2397_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134(5):703\u2013707. https:\/\/doi.org\/10.1016\/j.cell.2008.08.021","journal-title":"Cell"},{"issue":"3","key":"2397_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s13402-023-00909-3","volume":"47","author":"M Huang","year":"2024","unstructured":"Huang M, Liu Y, Yan Q et al (2024) NK cells as powerful therapeutic tool in cancer immunotherapy. Cell Oncol (Dordr) 47(3):733\u2013757. https:\/\/doi.org\/10.1007\/s13402-023-00909-3","journal-title":"Cell Oncol (Dordr)"},{"issue":"11","key":"2397_CR46","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.Can-14-2788","volume":"75","author":"HB Jie","year":"2015","unstructured":"Jie HB, Schuler PJ, Lee SC et al (2015) CTLA-4\u207a regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75(11):2200\u20132210. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-2788","journal-title":"Cancer Res"},{"issue":"1","key":"2397_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.apsb.2017.12.002","volume":"8","author":"K Jin","year":"2018","unstructured":"Jin K, Luo Z, Zhang B et al (2018) Biomimetic nanoparticles for inflammation targeting. Acta Pharm Sin B 8(1):23\u201333. https:\/\/doi.org\/10.1016\/j.apsb.2017.12.002","journal-title":"Acta Pharm Sin B"},{"key":"2397_CR48","doi-asserted-by":"publisher","unstructured":"Klapdor R, Wang S, Morgan MA et al (2021) NK cell-mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44. Biomedicines 9(10). https:\/\/doi.org\/10.3390\/biomedicines9101339","DOI":"10.3390\/biomedicines9101339"},{"issue":"9","key":"2397_CR49","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","volume":"4","author":"PA Konstantinopoulos","year":"2023","unstructured":"Konstantinopoulos PA, Matulonis UA (2023) Clinical and translational advances in ovarian cancer therapy. Nat Cancer 4(9):1239\u20131257. https:\/\/doi.org\/10.1038\/s43018-023-00617-9","journal-title":"Nat Cancer"},{"key":"2397_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","volume":"41","author":"O Kyrysyuk","year":"2023","unstructured":"Kyrysyuk O, Wucherpfennig KW (2023) Designing cancer immunotherapies that engage T cells and NK cells. Annu Rev Immunol 41:17\u201338. https:\/\/doi.org\/10.1146\/annurev-immunol-101921-044122","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"2397_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K (2022) Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer 22(10):557\u2013575. https:\/\/doi.org\/10.1038\/s41568-022-00491-0","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2397_CR52","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1073\/pnas.0712310105","volume":"105","author":"C Li","year":"2008","unstructured":"Li C, Ge B, Nicotra M et al (2008) JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci U S A 105(8):3017\u20133022. https:\/\/doi.org\/10.1073\/pnas.0712310105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2397_CR55","doi-asserted-by":"publisher","first-page":"830570","DOI":"10.3389\/fonc.2022.830570","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Tian W, Zhang H et al (2022) MSLN correlates with immune infiltration and chemoresistance as a prognostic biomarker in ovarian cancer. Front Oncol 12:830570. https:\/\/doi.org\/10.3389\/fonc.2022.830570","journal-title":"Front Oncol"},{"key":"2397_CR53","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, Niu M, Zhang W et al (2024a) CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol 15:1361194. https:\/\/doi.org\/10.3389\/fimmu.2024.1361194","journal-title":"Front Immunol"},{"issue":"7","key":"2397_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-024-02266-y","volume":"38","author":"Y Li","year":"2024","unstructured":"Li Y, Chen K, Chen B et al (2024b) Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK\/T-cell lymphoma. Leukemia 38(7):1553\u20131563. https:\/\/doi.org\/10.1038\/s41375-024-02266-y","journal-title":"Leukemia"},{"issue":"3","key":"2397_CR56","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci 41(3):211\u2013218. https:\/\/doi.org\/10.1016\/j.tibs.2015.12.001","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"2397_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41590-023-01523-z","volume":"24","author":"Z Lin","year":"2023","unstructured":"Lin Z, Bashirova AA, Viard M et al (2023) HLA class I signal peptide polymorphism determines the level of CD94\/NKG2-HLA-E-mediated regulation of effector cell responses. Nat Immunol 24(7):1087\u20131097. https:\/\/doi.org\/10.1038\/s41590-023-01523-z","journal-title":"Nat Immunol"},{"issue":"6","key":"2397_CR58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P et al (2020) Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 382(6):545\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa1910607","journal-title":"N Engl J Med"},{"issue":"5","key":"2397_CR59","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.14336\/ad.2022.0415","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Luo Q, Luo W et al (2022) A soluble NK-CAR mediates the specific cytotoxicity of NK cells toward the target CD20(+) lymphoma cells. Aging Dis 13(5):1576\u20131588. https:\/\/doi.org\/10.14336\/ad.2022.0415","journal-title":"Aging Dis"},{"issue":"2","key":"2397_CR60","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ccell.2023.01.001","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu X, Song J, Zhang H et al (2023) Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41(2):272\u2013287e9. https:\/\/doi.org\/10.1016\/j.ccell.2023.01.001","journal-title":"Cancer Cell"},{"issue":"1","key":"2397_CR61","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1038\/s41467-018-04719-2","volume":"9","author":"RM Loftus","year":"2018","unstructured":"Loftus RM, Assmann N, Kedia-Mehta N et al (2018) Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun 9(1):2341. https:\/\/doi.org\/10.1038\/s41467-018-04719-2","journal-title":"Nat Commun"},{"issue":"9","key":"2397_CR62","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/cac2.12330","volume":"42","author":"H Lou","year":"2022","unstructured":"Lou H, Cao X (2022) Antibody variable region engineering for improving cancer immunotherapy. Cancer Commun (Lond) 42(9):804\u2013827. https:\/\/doi.org\/10.1002\/cac2.12330","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"2397_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-025-02158-2","volume":"10","author":"J Luo","year":"2025","unstructured":"Luo J, Guo M, Huang M et al (2025) Neoleukin-2\/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc\/NRF1 activation. Signal Transduct Target Ther 10(1):78. https:\/\/doi.org\/10.1038\/s41392-025-02158-2","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2397_CR64","doi-asserted-by":"publisher","first-page":"1843247","DOI":"10.1080\/2162402x.2020.1843247","volume":"9","author":"RJ Maas","year":"2020","unstructured":"Maas RJ, Hoogstad-van Evert JS, Van der Meer JM et al (2020) TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1\/TIGIT\/CD96 checkpoint molecules in ovarian cancer. Oncoimmunology 9(1):1843247. https:\/\/doi.org\/10.1080\/2162402x.2020.1843247","journal-title":"Oncoimmunology"},{"issue":"3","key":"2397_CR65","doi-asserted-by":"publisher","first-page":"1557030","DOI":"10.1080\/2162402x.2018.1557030","volume":"8","author":"FR Mariotti","year":"2019","unstructured":"Mariotti FR, Petrini S, Ingegnere T et al (2019) PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology 8(3):1557030. https:\/\/doi.org\/10.1080\/2162402x.2018.1557030","journal-title":"Oncoimmunology"},{"issue":"1","key":"2397_CR66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.tcb.2013.09.005","volume":"24","author":"NB Mart\u00edn-C\u00f3freces","year":"2014","unstructured":"Mart\u00edn-C\u00f3freces NB, Baixauli F, S\u00e1nchez-Madrid F (2014) Immune synapse: conductor of orchestrated organelle movement. Trends Cell Biol 24(1):61\u201372. https:\/\/doi.org\/10.1016\/j.tcb.2013.09.005","journal-title":"Trends Cell Biol"},{"issue":"3","key":"2397_CR67","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2013-01-481705","volume":"122","author":"J Matta","year":"2013","unstructured":"Matta J, Baratin M, Chiche L et al (2013) Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 122(3):394\u2013404. https:\/\/doi.org\/10.1182\/blood-2013-01-481705","journal-title":"Blood"},{"issue":"5","key":"2397_CR68","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/s41385-018-0016-5","volume":"11","author":"T Mayassi","year":"2018","unstructured":"Mayassi T, Jabri B (2018) Human intraepithelial lymphocytes. Mucosal Immunol 11(5):1281\u20131289. https:\/\/doi.org\/10.1038\/s41385-018-0016-5","journal-title":"Mucosal Immunol"},{"issue":"12","key":"2397_CR69","doi-asserted-by":"publisher","first-page":"e1154251","DOI":"10.1080\/2162402x.2016.1154251","volume":"5","author":"M Messaoudene","year":"2016","unstructured":"Messaoudene M, Fregni G, Enot D et al (2016) NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution. Oncoimmunology 5(12):e1154251. https:\/\/doi.org\/10.1080\/2162402x.2016.1154251","journal-title":"Oncoimmunology"},{"issue":"1","key":"2397_CR70","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41598-019-38766-6","volume":"9","author":"H Mir","year":"2019","unstructured":"Mir H, Kaur G, Kapur N et al (2019) Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation. Sci Rep 9(1):2527. https:\/\/doi.org\/10.1038\/s41598-019-38766-6","journal-title":"Sci Rep"},{"issue":"9","key":"2397_CR71","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","volume":"31","author":"MR Mirza","year":"2020","unstructured":"Mirza MR, Coleman RL, Gonz\u00e1lez-Mart\u00edn A et al (2020) The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol 31(9):1148\u20131159. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.004","journal-title":"Ann Oncol"},{"issue":"11","key":"2397_CR72","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41418-023-01229-7","volume":"30","author":"T Mondal","year":"2023","unstructured":"Mondal T, Gaur H, Wamba BEN et al (2023) Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Differ 30(11):2408\u20132431. https:\/\/doi.org\/10.1038\/s41418-023-01229-7","journal-title":"Cell Death Differ"},{"key":"2397_CR73","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2007.00538.x","volume":"218","author":"A Mor","year":"2007","unstructured":"Mor A, Dustin ML, Philips MR (2007) Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunol Rev 218:114\u2013125. https:\/\/doi.org\/10.1111\/j.1600-065X.2007.00538.x","journal-title":"Immunol Rev"},{"issue":"4","key":"2397_CR74","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","volume":"20","author":"E Morand","year":"2024","unstructured":"Morand E, Merola JF, Tanaka Y et al (2024) TYK2: an emerging therapeutic target in rheumatic disease. Nat Rev Rheumatol 20(4):232\u2013240. https:\/\/doi.org\/10.1038\/s41584-024-01093-w","journal-title":"Nat Rev Rheumatol"},{"key":"2397_CR75","doi-asserted-by":"publisher","first-page":"1441730","DOI":"10.3389\/fimmu.2024.1441730","volume":"15","author":"K Murakami","year":"2024","unstructured":"Murakami K, Ganguly S (2024) The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy. Front Immunol 15:1441730. https:\/\/doi.org\/10.3389\/fimmu.2024.1441730","journal-title":"Front Immunol"},{"issue":"3","key":"2397_CR76","doi-asserted-by":"publisher","first-page":"e56685","DOI":"10.7759\/cureus.56685","volume":"16","author":"H Nagai","year":"2024","unstructured":"Nagai H, Karube R (2024) Late-stage ovarian cancer with systemic multiple metastases shows marked shrinkage using a combination of wilms\u2019 tumor antigen 1 (WT1) dendritic cell vaccine, natural killer (NK) cell therapy, and nivolumab. Cureus 16(3):e56685. https:\/\/doi.org\/10.7759\/cureus.56685","journal-title":"Cureus"},{"issue":"11","key":"2397_CR77","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV et al (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498\u20131503. https:\/\/doi.org\/10.1038\/nm.2492","journal-title":"Nat Med"},{"key":"2397_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY et al (2020) Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 65:189\u2013196. https:\/\/doi.org\/10.1016\/j.semcancer.2019.11.013","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"2397_CR79","doi-asserted-by":"publisher","first-page":"101827","DOI":"10.1016\/j.xcrm.2024.101827","volume":"5","author":"J Obajdin","year":"2024","unstructured":"Obajdin J, Larcombe-Young D, Glover M et al (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell Rep Med 5(11):101827. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101827","journal-title":"Cell Rep Med"},{"issue":"3","key":"2397_CR80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41590-022-01394-w","volume":"24","author":"SC Oh","year":"2023","unstructured":"Oh SC, Kim SE, Jang IH et al (2023) NgR1 is an NK cell inhibitory receptor that destabilizes the immunological synapse. Nat Immunol 24(3):463\u2013473. https:\/\/doi.org\/10.1038\/s41590-022-01394-w","journal-title":"Nat Immunol"},{"issue":"5","key":"2397_CR81","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/ijc.28114","volume":"133","author":"T Ohashi","year":"2013","unstructured":"Ohashi T, Akazawa T, Aoki M et al (2013) Dichloroacetate improves immune dysfunction caused by tumor-secreted lactic acid and increases antitumor immunoreactivity. Int J Cancer 133(5):1107\u20131118. https:\/\/doi.org\/10.1002\/ijc.28114","journal-title":"Int J Cancer"},{"issue":"4","key":"2397_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20191290","volume":"217","author":"G Okumura","year":"2020","unstructured":"Okumura G, Iguchi-Manaka A, Murata R et al (2020) Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells. J Exp Med 217(4):1. https:\/\/doi.org\/10.1084\/jem.20191290","journal-title":"J Exp Med"},{"issue":"17","key":"2397_CR84","doi-asserted-by":"publisher","first-page":"11351","DOI":"10.1073\/pnas.162376099","volume":"99","author":"JS Orange","year":"2002","unstructured":"Orange JS, Ramesh N, Remold-O\u2019Donnell E et al (2002) Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci U S A 99(17):11351\u201311356. https:\/\/doi.org\/10.1073\/pnas.162376099","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"2397_CR83","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.1073\/pnas.1835830100","volume":"100","author":"JS Orange","year":"2003","unstructured":"Orange JS, Harris KE, Andzelm MM et al (2003) The mature activating natural killer cell immunologic synapse is formed in distinct stages. Proc Natl Acad Sci U S A 100(24):14151\u201314156. https:\/\/doi.org\/10.1073\/pnas.1835830100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2397_CR85","doi-asserted-by":"publisher","first-page":"e2117065119","DOI":"10.1073\/pnas.2117065119","volume":"119","author":"D Ozmadenci","year":"2022","unstructured":"Ozmadenci D, Shankara Narayanan JS, Andrew J et al (2022) Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155\/TIGIT axis. Proc Natl Acad Sci U S A 119(17):e2117065119. https:\/\/doi.org\/10.1073\/pnas.2117065119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2397_CR86","doi-asserted-by":"publisher","unstructured":"Pankowska KA, B\u0119dkowska GE, Chociej-Stypu\u0142kowska J et al (2023) Crosstalk of immune cells and platelets in an ovarian cancer microenvironment and their prognostic significance. Int J Mol Sci 24(11). https:\/\/doi.org\/10.3390\/ijms24119279","DOI":"10.3390\/ijms24119279"},{"key":"2397_CR87","doi-asserted-by":"publisher","unstructured":"Paolini R, Molfetta R (2023) CD155 and Its receptors as targets for cancer therapy. Int J Mol Sci 24(16). https:\/\/doi.org\/10.3390\/ijms241612958","DOI":"10.3390\/ijms241612958"},{"key":"2397_CR88","doi-asserted-by":"publisher","unstructured":"Paw\u0142owska A, Skiba W, Suszczyk D et al (2022) The dual blockade of the TIGIT and PD-1\/PD-L1 pathway as a new hope for ovarian cancer patients. Cancers (Basel) 14(23). https:\/\/doi.org\/10.3390\/cancers14235757","DOI":"10.3390\/cancers14235757"},{"issue":"4","key":"2397_CR90","doi-asserted-by":"publisher","first-page":"e1001224","DOI":"10.1080\/2162402x.2014.1001224","volume":"4","author":"S Pesce","year":"2015","unstructured":"Pesce S, Tabellini G, Cantoni C et al (2015) B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 4(4):e1001224. https:\/\/doi.org\/10.1080\/2162402x.2014.1001224","journal-title":"Oncoimmunology"},{"issue":"1","key":"2397_CR89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G et al (2017) Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol 139(1):335\u2013346e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.04.025","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2397_CR91","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager I, Liesche C, van Ooijen H et al (2019) NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J Exp Med 216(9):2113\u20132127. https:\/\/doi.org\/10.1084\/jem.20181454","journal-title":"J Exp Med"},{"issue":"25","key":"2397_CR92","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"2397_CR93","doi-asserted-by":"publisher","unstructured":"Ren X, Peng M, Xing P et al (2022) Blockade of the immunosuppressive KIR2DL5\/PVR pathway elicits potent human NK cell-mediated antitumor immunity. J Clin Invest 132(22). https:\/\/doi.org\/10.1172\/jci163620","DOI":"10.1172\/jci163620"},{"key":"2397_CR94","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54854","author":"Y Robbins","year":"2020","unstructured":"Robbins Y, Greene S, Friedman J et al (2020) Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife 9. https:\/\/doi.org\/10.7554\/eLife.54854","journal-title":"Elife 9"},{"issue":"6","key":"2397_CR95","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3892\/ijo_00000788","volume":"37","author":"I Rousalova","year":"2010","unstructured":"Rousalova I, Krepela E (2010) Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 37(6):1361\u20131378. https:\/\/doi.org\/10.3892\/ijo_00000788","journal-title":"Int J Oncol"},{"issue":"11","key":"2397_CR96","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00109-021-02123-w","volume":"99","author":"A Salminen","year":"2021","unstructured":"Salminen A (2021) Immunosuppressive network promotes immunosenescence associated with aging and chronic inflammatory conditions. J Mol Med (Berl) 99(11):1553\u20131569. https:\/\/doi.org\/10.1007\/s00109-021-02123-w","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"2397_CR97","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nri2711","volume":"10","author":"M Saraiva","year":"2010","unstructured":"Saraiva M, O\u2019Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170\u2013181. https:\/\/doi.org\/10.1038\/nri2711","journal-title":"Nat Rev Immunol"},{"key":"2397_CR98","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fimmu.2020.00040","volume":"11","author":"EC Sayitoglu","year":"2020","unstructured":"Sayitoglu EC, Georgoudaki AM, Chrobok M et al (2020) Boosting natural killer cell-mediated targeting of sarcoma through DNAM-1 and NKG2D. Front Immunol 11:40. https:\/\/doi.org\/10.3389\/fimmu.2020.00040","journal-title":"Front Immunol"},{"issue":"3","key":"2397_CR99","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/med.20025","volume":"25","author":"M Scholz","year":"2005","unstructured":"Scholz M, Cinatl J (2005) Fas\/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 25(3):331\u2013342. https:\/\/doi.org\/10.1002\/med.20025","journal-title":"Med Res Rev"},{"issue":"11","key":"2397_CR100","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/0008-5472.Can-20-2701","volume":"81","author":"E Schoutrop","year":"2021","unstructured":"Schoutrop E, El-Serafi I, Poiret T et al (2021) Mesothelin-specific CAR T cells target ovarian cancer. Cancer Res 81(11):3022\u20133035. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-2701","journal-title":"Cancer Res"},{"key":"2397_CR101","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fimmu.2016.00492","volume":"7","author":"M Shevtsov","year":"2016","unstructured":"Shevtsov M, Multhoff G (2016) Immunological and translational aspects of NK cell-based antitumor immunotherapies. Front Immunol 7:492. https:\/\/doi.org\/10.3389\/fimmu.2016.00492","journal-title":"Front Immunol"},{"issue":"1","key":"2397_CR102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2397_CR103","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.cell.2007.03.037","volume":"129","author":"TN Sims","year":"2007","unstructured":"Sims TN, Soos TJ, Xenias HS et al (2007) Opposing effects of PKCtheta and WASp on symmetry breaking and relocation of the immunological synapse. Cell 129(4):773\u2013785. https:\/\/doi.org\/10.1016\/j.cell.2007.03.037","journal-title":"Cell"},{"key":"2397_CR104","doi-asserted-by":"publisher","first-page":"114205","DOI":"10.1016\/j.ejmech.2022.114205","volume":"232","author":"M Song","year":"2022","unstructured":"Song M, Cui M, Liu K (2022) Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem 232:114205. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114205","journal-title":"Eur J Med Chem"},{"issue":"51","key":"2397_CR105","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/pnas.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H et al (2017) Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A 114(51):E10981\u2013e10990. https:\/\/doi.org\/10.1073\/pnas.1712514114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2397_CR106","doi-asserted-by":"publisher","unstructured":"Sun E, Motolani A, Campos L et al (2022) The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer\u2019s disease. Int J Mol Sci 23(16). https:\/\/doi.org\/10.3390\/ijms23168972","DOI":"10.3390\/ijms23168972"},{"key":"2397_CR107","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.imlet.2019.10.006","volume":"216","author":"I Tahrali","year":"2019","unstructured":"Tahrali I, Kucuksezer UC, Akdeniz N et al (2019) CD3(-)CD56(+) NK cells display an inflammatory profile in RR-MS patients. Immunol Lett 216:63\u201369. https:\/\/doi.org\/10.1016\/j.imlet.2019.10.006","journal-title":"Immunol Lett"},{"issue":"28","key":"2397_CR108","doi-asserted-by":"publisher","first-page":"eadn0881","DOI":"10.1126\/sciadv.adn0881","volume":"10","author":"M Tarannum","year":"2024","unstructured":"Tarannum M, Dinh K, Vergara J et al (2024) CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer. Sci Adv 10(28):eadn0881. https:\/\/doi.org\/10.1126\/sciadv.adn0881","journal-title":"Sci Adv"},{"key":"2397_CR109","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","volume":"10","author":"I Terr\u00e9n","year":"2019","unstructured":"Terr\u00e9n I, Orrantia A, Vitall\u00e9 J et al (2019) NK cell metabolism and tumor microenvironment. Front Immunol 10:2278. https:\/\/doi.org\/10.3389\/fimmu.2019.02278","journal-title":"Front Immunol"},{"key":"2397_CR110","doi-asserted-by":"publisher","unstructured":"Tonetti CR, de Souza-Ara\u00fajo CN, Yoshida A et al (2021) Ovarian cancer-associated ascites have high proportions of cytokine-responsive CD56bright NK cells. Cells 10(7). https:\/\/doi.org\/10.3390\/cells10071702","DOI":"10.3390\/cells10071702"},{"issue":"1","key":"2397_CR111","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jim\u00e9nez-Cortegana C, Tay AHM et al (2022) NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer 21(1):206. https:\/\/doi.org\/10.1186\/s12943-022-01672-z","journal-title":"Mol Cancer"},{"key":"2397_CR112","doi-asserted-by":"publisher","first-page":"867098","DOI":"10.3389\/fimmu.2022.867098","volume":"13","author":"K Tuomela","year":"2022","unstructured":"Tuomela K, Ambrose AR, Davis DM (2022) Escaping death: how cancer cells and infected cells resist cell-mediated cytotoxicity. Front Immunol 13:867098. https:\/\/doi.org\/10.3389\/fimmu.2022.867098","journal-title":"Front Immunol"},{"issue":"5","key":"2397_CR113","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/cas.14374","volume":"111","author":"T Ueda","year":"2020","unstructured":"Ueda T, Kumagai A, Iriguchi S et al (2020) Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci 111(5):1478\u20131490. https:\/\/doi.org\/10.1111\/cas.14374","journal-title":"Cancer Sci"},{"issue":"1","key":"2397_CR114","doi-asserted-by":"publisher","first-page":"1981049","DOI":"10.1080\/2162402x.2021.1981049","volume":"10","author":"JMR Van der Meer","year":"2021","unstructured":"Van der Meer JMR, de Jonge P, van der Waart AB et al (2021) CD34(+) progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD\/SCID\/IL2Rg(null) mice. Oncoimmunology 10(1):1981049. https:\/\/doi.org\/10.1080\/2162402x.2021.1981049","journal-title":"Oncoimmunology"},{"issue":"7941","key":"2397_CR115","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","volume":"612","author":"I V\u00e1zquez-Garc\u00eda","year":"2022","unstructured":"V\u00e1zquez-Garc\u00eda I, Uhlitz F, Ceglia N et al (2022) Ovarian cancer mutational processes drive site-specific immune evasion. Nature 612(7941):778\u2013786. https:\/\/doi.org\/10.1038\/s41586-022-05496-1","journal-title":"Nature"},{"issue":"32","key":"2397_CR116","doi-asserted-by":"publisher","first-page":"27204","DOI":"10.1074\/jbc.M112.376616","volume":"287","author":"NK Verma","year":"2012","unstructured":"Verma NK, Dempsey E, Long A et al (2012) Leukocyte function-associated antigen-1\/intercellular adhesion molecule-1 interaction induces a novel genetic signature resulting in T-cells refractory to transforming growth factor-\u03b2 signaling. J Biol Chem 287(32):27204\u201327216. https:\/\/doi.org\/10.1074\/jbc.M112.376616","journal-title":"J Biol Chem"},{"key":"2397_CR117","doi-asserted-by":"publisher","unstructured":"Viel S, Besson L, Marotel M et al (2017) Regulation of mTOR, metabolic fitness, and effector functions by cytokines in natural killer cells. Cancers (Basel) 9(10). https:\/\/doi.org\/10.3390\/cancers9100132","DOI":"10.3390\/cancers9100132"},{"key":"2397_CR118","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","volume":"35","author":"DS Vinay","year":"2015","unstructured":"Vinay DS, Ryan EP, Pawelec G et al (2015) Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 35:S185\u2013s198. https:\/\/doi.org\/10.1016\/j.semcancer.2015.03.004","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2397_CR119","doi-asserted-by":"publisher","first-page":"e1339854","DOI":"10.1080\/2162402x.2017.1339854","volume":"6","author":"M Vyas","year":"2017","unstructured":"Vyas M, Reinartz S, Hoffmann N et al (2017) Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology 6(9):e1339854. https:\/\/doi.org\/10.1080\/2162402x.2017.1339854","journal-title":"Oncoimmunology"},{"issue":"1","key":"2397_CR120","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/0008-5472.Can-20-1674","volume":"81","author":"C Wan","year":"2021","unstructured":"Wan C, Keany MP, Dong H et al (2021) Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer. Cancer Res 81(1):158\u2013173. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-1674","journal-title":"Cancer Res"},{"key":"2397_CR121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.canlet.2021.09.003","volume":"521","author":"J Wang","year":"2021","unstructured":"Wang J, Dai Z, Miao Y et al (2021) Carbon ion ((12)C(6+)) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D\/NKG2D-Ls pathway. Cancer Lett 521:178\u2013195. https:\/\/doi.org\/10.1016\/j.canlet.2021.09.003","journal-title":"Cancer Lett"},{"key":"2397_CR122","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","volume":"41","author":"PM Webb","year":"2017","unstructured":"Webb PM, Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41:3\u201314. https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.08.006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"8","key":"2397_CR123","doi-asserted-by":"publisher","first-page":"110847","DOI":"10.1016\/j.celrep.2022.110847","volume":"39","author":"LP Westhaver","year":"2022","unstructured":"Westhaver LP, Nersesian S, Nelson A et al (2022) Mitochondrial damage-associated molecular patterns trigger arginase-dependent lymphocyte immunoregulation. Cell Rep 39(8):110847. https:\/\/doi.org\/10.1016\/j.celrep.2022.110847","journal-title":"Cell Rep"},{"issue":"2","key":"2397_CR124","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00262-009-0749-9","volume":"59","author":"X Wu","year":"2010","unstructured":"Wu X, Feng QM, Wang Y et al (2010) The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother 59(2):279\u2013291. https:\/\/doi.org\/10.1007\/s00262-009-0749-9","journal-title":"Cancer Immunol Immunother"},{"key":"2397_CR125","doi-asserted-by":"publisher","unstructured":"Xia Y, Huang P, Qian YY et al (2024) PARP inhibitors enhance antitumor immune responses by triggering pyroptosis via TNF-caspase 8-GSDMD\/E axis in ovarian cancer. J Immunother Cancer 12(10). https:\/\/doi.org\/10.1136\/jitc-2024-009032","DOI":"10.1136\/jitc-2024-009032"},{"key":"2397_CR126","doi-asserted-by":"publisher","unstructured":"Xing Z, Li X, He ZNT et al (2024) IDO1 inhibitor RY103 suppresses Trp-GCN2-mediated angiogenesis and counters immunosuppression in glioblastoma. Pharmaceutics 16(7). https:\/\/doi.org\/10.3390\/pharmaceutics16070870","DOI":"10.3390\/pharmaceutics16070870"},{"issue":"1","key":"2397_CR127","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s12967-021-03119-3","volume":"19","author":"M Xu","year":"2021","unstructured":"Xu M, Huang S, Chen J et al (2021) Cytotoxic lymphocytes-related gene ITK from a systematic CRISPR screen could predict prognosis of ovarian cancer patients with distant metastasis. J Transl Med 19(1):447. https:\/\/doi.org\/10.1186\/s12967-021-03119-3","journal-title":"J Transl Med"},{"issue":"4","key":"2397_CR128","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/cas.13958","volume":"110","author":"T Yahata","year":"2019","unstructured":"Yahata T, Mizoguchi M, Kimura A et al (2019) Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats\/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci 110(4):1279\u20131292. https:\/\/doi.org\/10.1111\/cas.13958","journal-title":"Cancer Sci"},{"key":"2397_CR129","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3389\/fimmu.2017.00403","volume":"8","author":"A Yamada","year":"2017","unstructured":"Yamada A, Arakaki R, Saito M et al (2017) Dual role of Fas\/FasL-mediated signal in peripheral immune tolerance. Front Immunol 8:403. https:\/\/doi.org\/10.3389\/fimmu.2017.00403","journal-title":"Front Immunol"},{"issue":"6","key":"2397_CR131","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.it.2010.04.002","volume":"31","author":"L Yang","year":"2010","unstructured":"Yang L, Pang Y, Moses HL (2010) TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31(6):220\u2013227. https:\/\/doi.org\/10.1016\/j.it.2010.04.002","journal-title":"Trends Immunol"},{"key":"2397_CR130","doi-asserted-by":"publisher","first-page":"112588","DOI":"10.1016\/j.jphotobiol.2022.112588","volume":"237","author":"L Yang","year":"2022","unstructured":"Yang L, Ma C, Tai S et al (2022) Mechanism of selective induction of apoptosis of HCT116 tumor cells in circulating blood by riboflavin photochemistry. J Photochem Photobiol B 237:112588. https:\/\/doi.org\/10.1016\/j.jphotobiol.2022.112588","journal-title":"J Photochem Photobiol B"},{"key":"2397_CR133","doi-asserted-by":"publisher","first-page":"728291","DOI":"10.3389\/fimmu.2021.728291","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wei H (2021) Role of decidual natural killer cells in human pregnancy and related pregnancy complications. Front Immunol 12:728291. https:\/\/doi.org\/10.3389\/fimmu.2021.728291","journal-title":"Front Immunol"},{"issue":"5","key":"2397_CR132","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.4049\/jimmunol.1103495","volume":"189","author":"T Zhang","year":"2012","unstructured":"Zhang T, Wu MR, Sentman CL (2012) An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol 189(5):2290\u20132299. https:\/\/doi.org\/10.4049\/jimmunol.1103495","journal-title":"J Immunol"},{"key":"2397_CR134","doi-asserted-by":"publisher","unstructured":"Zhou Y, Bastian IN, Long MD et al (2021) Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A 118(8). https:\/\/doi.org\/10.1073\/pnas.2025840118","DOI":"10.1073\/pnas.2025840118"},{"issue":"5","key":"2397_CR135","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.3802\/jgo.2017.28.e64","volume":"28","author":"X Zhu","year":"2017","unstructured":"Zhu X, Lang J (2017) Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. J Gynecol Oncol 28(5):e64. https:\/\/doi.org\/10.3802\/jgo.2017.28.e64","journal-title":"J Gynecol Oncol"},{"key":"2397_CR136","doi-asserted-by":"publisher","unstructured":"Zo\u0144 A, Bednarek I (2023) Cisplatin in ovarian cancer treatment-known limitations in therapy force new solutions. Int J Mol Sci 24(8). https:\/\/doi.org\/10.3390\/ijms24087585","DOI":"10.3390\/ijms24087585"},{"key":"2397_CR137","doi-asserted-by":"publisher","unstructured":"Zwirner NW, Fuertes MB, Girart MV et al (2007) Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18(1\u20132) 159\u2009\u2013\u200970. https:\/\/doi.org\/10.1016\/j.cytogfr.2007.01.013","DOI":"10.1016\/j.cytogfr.2007.01.013"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02397-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02397-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:55:20Z","timestamp":1792194920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02397-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2397"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02397-x","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"28 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}